Lilly
Recent news mentioning Lilly
- — Lilly Scores FDA Win for Pancreatic Cancer Drug. How It’s Moving Beyond GLP-1s.
- — Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
- — Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- — Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- — Pharmakonzern: „Mein Vertrauen ist zerstört“: Eli-Lilly-Chef rechnet mit deutscher Gesundheitspolitik ab
- — Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs - Barron's
- — How Eli Lilly Just Extended Its Lead in the Weight-Loss Drug Market - Barron's
- — Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
- — Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- — Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
- — Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
- — Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial